|
Centre for Policy on Ageing | |
 | |
|
Alzheimer's CSF markers in older schizophrenia patients | Author(s) | Giovanni B Frisoni, Annapaola Prestia, Cristina Geroldi |
Journal title | International Journal of Geriatric Psychiatry, vol 26, no 6, June 2011 |
Pages | pp 640-648 |
Source | http://www.interscience.wiley.com/journal/gps |
Keywords | Dementia ; Schizophrenia ; Evaluation ; Diagnosis ; Cognitive processes ; Clinical surveys. |
Annotation | The study investigated the neuropathology of Alzheimer's disease (AD) in older patients with schizophrenia. The authors looked at the concentrations of cerebrospinal fluid (CSF) biomarkers of brain amyloidosis (Abeta42) and neurodegeneration (total and p-tau) in a group of older schizophrenia patients and related them to cognitive and magnetic resonance imaging (MRI) measures. Older schizophrenia, AD patients and older controls underwent cognitive testing, lumbar puncture, and MRI scanning. Abeta42 and total and p-tau concentrations were assayed in the CSF. MRI volumes were assessed using both voxel-based (cortical pattern matching) and region-of-interest analyses. Results showed that CSF tau concentration in older schizophrenia patients was within normal limits, while CSF Abeta42 levels were significantly lower compared to healthy older people but higher than in AD patients. There was a strong positive relationship between CSF total or p-tau levels and mini mental state examination (MMSE) scores in schizophrenia patients but not in AD, where higher concentrations of total tau were correlated with higher volumes in the occipital cortex, while in AD a significant correlation was found between lower Abeta42 concentrations and lower grey matter volume in the cingulate and lateral orbital cortices. In conclusion, older schizophrenia patients show a peculiar pattern of CSF Abeta42 and tau concentrations that relates to cognitive and structural markers but is not consistent with neurodegeneration and could be secondary to neurodevelopmental or drug treatment effects. (JL). |
Accession Number | CPA-110822008 A |
Classmark | EA: ELK: 4C: LK7: DA: 3G |
Data © Centre for Policy on Ageing |
|
...from the Ageinfo database published by Centre for Policy on Ageing. |
| |
|